Company intelligence / Profile preview

New Impact

Ownership: Private
Development stage: Other

Overview

Interim results from the pivotal Phase 3 ENLIGHTED study show that Padeliporfin VTP achieved a complete response rate of 73% and partial response rate of 13.5% among evaluable patients with low-grade UTUC at interim analysis. The treatment offers surgery-like efficacy without organ loss or injury and continues to enroll patients toward potential registration later this year. Earlier studies have shown promising long-term safety and efficacy data in prostate cancer as well.

Therapeutic areas: Oncology
Modalities: Small molecule (Padeliporfin)Device (Drug-device combination therapy)Photodynamic therapy (Vascular Targeted Photodynamic Therapy, VTP)
Industry: Biotech

Partnerships

Weizmann Institute of ScienceMemorial Sloan Kettering Cancer Center

Beyond the preview

Go deeper on New Impact.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on New Impact.

Explore the full profile